Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | XIAP | P98170 | 1/20 | 0.66 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | SDCBP | O00560 | 4/20 | 0.61 |
| ▸ | SDC2 | P34741 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311675 | 1.00 | ALOX15 (0.66) | ALOX15KDM4EALDH1A1TSHRXIAP | |
| SCHEMBL30856522 | 1.00 | ALOX15 (0.66) | ALOX15KDM4EALDH1A1TSHRXIAP | |
| SCHEMBL15338689 | 0.87 | ALOX15 (0.57) | ALOX15KDM4EALDH1A1TSHRXIAP | |
| SCHEMBL6051774 | 0.86 | ALOX15 (0.56) | ALOX15KDM4EALDH1A1TSHRXIAP | |
| SCHEMBL15110311 | 0.84 | SDCBP (0.74) | ALOX15KDM4EALDH1A1TSHRXIAP | |
| SCHEMBL15110161 | 0.84 | SDCBP (0.74) | ALOX15KDM4EALDH1A1TSHRXIAP | |
| SCHEMBL16266923 | 0.84 | SDCBP (0.74) | ALOX15KDM4EALDH1A1TSHRXIAP | |
| SCHEMBL31447067 | 0.84 | ALOX15 (0.51) | ALOX15KDM4EALDH1A1TSHRXIAP | |
| SCHEMBL8412252 | 0.84 | ALOX15 (0.51) | ALOX15KDM4EALDH1A1TSHRXIAP | |
| SCHEMBL24064921 | 0.82 | SDCBP (0.46) | ALOX15KDM4EALDH1A1TSHRXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114948963-B | Benzolactam compounds as protein kinase inhibitors | 大冢制药株式会社 | 2025-05-27 | — | — | CN | disclosed |
| US-12275723-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-15 | — | — | US | disclosed |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-05 | — | — | US | disclosed |
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-09-26 | — | — | US | disclosed |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-12 | — | — | US | disclosed |
| US-11970486-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-30 | — | — | US | disclosed |
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-18 | — | — | US | disclosed |
| CN-117777121-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117736134-A | Compounds and methods for enhancing degradation of target proteins and other polypeptides by E3 ubiquitin ligases | 耶鲁大学 | 2024-03-22 | — | — | CN | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| EP-2366704-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2364984-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-7985762-B2 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-07 | — | — | US | disclosed |
| US-7964624-B1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-21 | — | — | US | disclosed |
| CN-101348455-A | Aspartic acid specificity cysteine proteinase inhibitors and uses thereof | VERTEX PHARMA (US) | 2009-01-21 | — | — | CN | disclosed |
| CN-100415718-C | Caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2008-09-03 | — | — | CN | disclosed |
| US-20070179167-A1 | Inhibitors of serine proteases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| CN-1420872-A | Caspase inhibitors and uses thereof | VERTEX PHARMA (US) | 2003-05-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124435-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ALOX15 557/4885KDM4E 2853/4885ALDH1A1 656/4885 |
| US-20240300938-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ALOX15 557/4885KDM4E 2853/4885ALDH1A1 656/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | ALOX15 557/4885KDM4E 2853/4885ALDH1A1 656/4885 |
| US-20240400546-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | ALOX15 557/4885KDM4E 2853/4885ALDH1A1 656/4885 |
| US-12275723-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | ALOX15 557/4885KDM4E 2853/4885ALDH1A1 656/4885 |
| US-20110165120-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, PRSS3, PRSS2 | ALOX15 3227/4885KDM4E 2603/4885ALDH1A1 1374/4885 |
| US-20070179167-A1 | Inhibitors of serine proteases | PRSS1, PRSS3, PRSS2 | ALOX15 3227/4885KDM4E 2603/4885ALDH1A1 1374/4885 |
| US-20240317729-A1 | Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase | MDM2, VHL, XIAP | ALOX15 4587/4885KDM4E 1321/4885ALDH1A1 2756/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | ALOX15 3225/4885KDM4E 1669/4885ALDH1A1 1255/4885 |
| US-11970486-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | ALOX15 557/4885KDM4E 2853/4885ALDH1A1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.